The sale of the ophthalmology business alone could earn the company around $5 billion, according to the report. Private equity firms are already studying the business.
Negotiations are ongoing, and if a sale happens it will likely happen in 2023, Bloomberg reported.
In 2019, Novartis spun-off its Alcon eyecare business. In August, it spun-off its generic-drugs unit.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.